Repligen CEO Tony Hunt to become Executive Chair; Olivier Loeillot appointed President and CEO effective Sept 1, 2024

REPLIGEN CORP

Tony Hunt transitions from CEO to Executive Chair effective Sept 1, 2024; Olivier Loeillot named President and CEO.
Loeillot, currently President & Chief Commercial Officer (since Oct 2023), will join the Board.
Current Board Chair Karen Dawes becomes Lead Independent Director effective Sept 1, 2024.
Under Hunt's 9-year tenure, Repligen revenue grew from ~$63M (2014) to $639M (2023), ~30% CAGR.
Loeillot has ~30 years industry experience, previously Bioprocess President at Cytiva.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.